Roche Partners with French Startup to Diagnose Septic Shock
In its first partnership with a biotech startup, Roche Diagnostics will help develop a blood test to accompany Inotrem’s experimental therapy for septic shock.
Roche Diagnostics has announced a research collaboration with Inotrem, a biotech startup based in Nancy, France. The deal, for which the amount was undisclosed, concerns the development of a companion diagnostic test to diagnose septic shock by measuring the levels of soluble TREM-1 protein in blood plasma.
High levels of soluble TREM-1 are associated with the activation of immune amplification pathways, and the protein is associated with negative outcomes in septic shock patients. Measuring it could help identify how severe is the condition in each patient, which, according to Inotrem CEO Jean-Jacques Garaud, is one of the main issues with the condition.
Inotrem is currently conducting a Phase II clinical trial with Motrem, a peptide drug that inhibits TREM-1. The development of a companion diagnostic would help the startup better identify which patients would benefit the most from this treatment.
Septic shock consists of an excessively intense inflammatory reaction to an infection that severely affects multiple organs and tissues. Inotrem is not the only one aiming to improve the diagnosis and treatment of such a life-threatening condition. The German Curetis is developing a rapid sepsis diagnostic to help doctors react faster to sepsis, while Adrenomed, also in Germany, is working on an antibody to treat septic shock.
Image via Csaba Deli / Shutterstock